Pomegranate and prostate
What 2 graded rows on pomegranate agree on for prostate, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Pomegranate page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Pomegranate page, with its PubMed record.
Your question
Pomegranate and prostate
2 rows · 281 peopleThey agree: both rows found no difference.
- DGrade D× 1
- ∅No effect× 1
- Rows
- 2
- Trials
- 2
- People
- 281
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 98 people (2013) and found no difference. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The rows run from 98 to 183 people, published from 2013 to 2015: 2 single studies.
The rows
2 no difference- DGrade DPSA levels in advanced prostate cancer · No difference
RCT · n 98 · 2013 · Men with prostate cancer and PSA of 5 ng/mL or more (68% castration-resistant)
500 mL/day for 4 weeks, then 250 mL/day for 4 weeks (both groups) · 8 weeks
No differences from placebo in PSA kinetics or pain scores; no grade 3 or higher toxicity.
Row on the Pomegranate page · PubMed 24069070 (opens PubMed)
- ∅No effectPSA doubling time after primary therapy for prostate cancer · No difference
RCT · n 183 · 2015 · Men with rising PSA after surgery or radiation for prostate cancer
Not stated in the abstract · Not stated in the abstract
Median PSA doubling time lengthened in every group, placebo included (11.1 to 15.6 months on placebo), with no significant difference between extract, juice and placebo. Men with the MnSOD AA genotype had a larger increase on extract (subgroup finding).
Row on the Pomegranate page · PubMed 26169045 (opens PubMed)